Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Zanubrutinib may be poised to challenge ibrutinib for CLL

Publish date:: August 15, 2019

Key clinical point: The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib appears safe and effective for patients with B-cell malignancies.

Major finding: The overall response rate among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was 96.2%.

Study details: A phase 1, open-label, dose-escalation/expansion study involving 144 patients with B-cell malignancies.

Disclosures: The study was funded by BeiGene USA, which is developing the drug. The investigators reported relationships with the study sponsor, as well as Janssen, Pharmacyclics, AbbVie, and others.

Citation:

Tam CSL et al. Blood. 2019 Jul 24. doi: 10.1182/blood.2019001160.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,